Invenire Partners’s OptimizeRx OPRX Stock Holding History

Invenire Partners’s Portfolio OPRX Stock Details OPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	$1.56M	Buy	+105,000	New	+$2.08M	2.38%	21

Other funds holding OPRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

William Blair & Company Chicago, Illinois $38.4B AUM 25.71% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

Avenir Corporation Alexandria, Virginia $821M AUM 4.23% 1-Year Est. Return

KCM

Kennedy Capital Management St Louis, Missouri $5.65B AUM 61.31% 1-Year Est. Return

AIC

AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return

GIPM

G2 Investment Partners Management New York $549M AUM 179.59% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return

Invenire Partners's OPRX Position: Q3 2022 in Review

Invenire Partners opened a new position in OptimizeRx (OPRX) in Q3 2022: 105,000 shares worth $1.56M. The stake represents 2.38% of the portfolio and ranks #21 among its holdings.

128 funds tracked by Wall St. Rank hold OPRX as of Q3 2022.

Invenire Partners held 105,000 shares of OptimizeRx worth $1.56M as of Q3 2022.
OptimizeRx was a new Invenire Partners position in Q3 2022.
OptimizeRx made up 2.38% of Invenire Partners's portfolio in Q3 2022, its #21 holding.
128 funds tracked by Wall St. Rank held OptimizeRx as of Q3 2022.

Based on Invenire Partners's 13F filing for Q3 2022, filed 14 Nov 2022.